DBV Technologies S.A. (NASDAQ:DBVT) Receives $48.50 Average Price Target from Analysts

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have received an average rating of “Moderate Buy” from the seven analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $48.50.

Several equities research analysts have commented on DBVT shares. Wall Street Zen cut shares of DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. Citigroup restated an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st. Guggenheim reaffirmed a “buy” rating and issued a $51.00 target price on shares of DBV Technologies in a research report on Monday, May 4th. Citizens Jmp upped their target price on DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a report on Tuesday, June 30th. Finally, Weiss Ratings cut DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 17th.

DBV Technologies Trading Down 1.9%

Shares of NASDAQ DBVT opened at $13.48 on Friday. DBV Technologies has a 1 year low of $8.70 and a 1 year high of $26.18. The firm’s 50-day moving average is $15.58 and its 200-day moving average is $19.01. The firm has a market capitalization of $798.29 million, a PE ratio of -3.84 and a beta of -0.93.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings results on Thursday, July 16th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.48). DBV Technologies had a negative net margin of 3,506.53% and a negative return on equity of 119.33%. The company had revenue of $0.70 million during the quarter, compared to analyst estimates of $0.90 million. As a group, equities research analysts anticipate that DBV Technologies will post -2.05 earnings per share for the current fiscal year.

Institutional Trading of DBV Technologies

A number of hedge funds have recently modified their holdings of the stock. Truvestments Capital LLC lifted its holdings in DBV Technologies by 71.3% in the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after buying an additional 1,620 shares during the period. Allworth Financial LP acquired a new stake in DBV Technologies during the 4th quarter worth about $32,000. Royal Bank of Canada acquired a new stake in DBV Technologies during the 4th quarter worth about $34,000. Persistent Asset Partners Ltd bought a new position in shares of DBV Technologies in the 4th quarter worth about $115,000. Finally, Cetera Investment Advisers raised its position in shares of DBV Technologies by 93.4% in the 1st quarter. Cetera Investment Advisers now owns 25,358 shares of the company’s stock worth $530,000 after acquiring an additional 12,243 shares in the last quarter. Institutional investors and hedge funds own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.